Why testing for TP53, del(17q), and IGHV status critical for treatment selection and outcome optimization. Here’s my take.
The implications of minimal residual disease status on treatment of CLL is evolving. Here’s my take on what you should know now.
Get the latest information on how investigational noncovalent BTK inhibitors, such as LOXO-305 and ARQ 531, may help treat patients with CLL and resistance to currently available BTK inhibitors.